Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)

v3.8.0.1
Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Apr. 20, 2017
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Jan. 23, 2018
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock, par value $ 0.001 $ 0.001   $ 0.001     $ 0.001
Common stock, shares authorized 100,000,000 400,000,000   400,000,000   400,000,000 400,000,000
Preferred stock, shares authorized 1,500,005 1,500,005   1,500,005      
Reverse stock split one-for-two hundred and fifty (1:250)            
Cash equivalents        
Value added tax receivable   2,357   2,357     $ 8,111
Research and development costs   75,138 $ 386,490 1,673,606 $ 714,889    
Research and development tax credit   $ 485 $ 306,159 $ 180,763 $ 306,159    
Stock Options [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Antidilutive securities excluded from computation of earnings per share, amount       572,000      
Convertible Notes Payable [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Antidilutive securities excluded from computation of earnings per share, amount       18      
Warrants [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Antidilutive securities excluded from computation of earnings per share, amount       149,517      
Common Stock [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Antidilutive securities excluded from computation of earnings per share, amount       57,448,803